News | July 11, 2023
Sumitomo Pharma America launches as new combined organization
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Cytel excels at using proven quantitative techniques to transform real-world data into actionable insights
The company has received Export Performance Award - API & Intermediaries Gold Star for the year 2021-22
Shareholding of the company in MIMS has increased from 76.01 per cent to 78.37 per cent
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments
Subscribe To Our Newsletter & Stay Updated
